Industry Committee

The Industry Committee supports CAHON’s mission and Clinical Research Committee from an industry perspective, and supports members who work in industry through resource sharing, clinical trials, etc. The Industry Committee is also responsible for fostering collaboration between academia, community, and industry members while also providing career coaching opportunities for young academic members who are interested in exploring industry opportunities.

Jianda Yuan, MD, PhD (Chair)

Dr. Jianda Yuan is the Senior Medical Director of Translational Oncology at Early Oncology Development Department of Merck Research Laboratory. He oversees several Merck sponsored Keytruda clinical trials and external academic collaborative clinical studies. He collaborates internally and externally scientific experts to develop a robust portfolio of research to answer critical questions about mechanisms of cancer immunotherapy response and resistance. Before he joined Merck in February, 2016, He established and led the translational biomarker research at Ludwig Center for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center from 2002 to 2016. His research interest is translational medicine and biomarker discovery for immune checkpoint blockade immunotherapy with approximately 70 peer-reviewed articles, including publication in Science, NEJM, Nature Medicine, Nature Immunology, PNAS, Blood, Journal of Immunology, Clinical Cancer Research and Journal Immunotherapy of Cancer. He is a member of SITC, COHAN, AACR and ASCO. Dr. Yuan is an Associate Editor of the Journal Immunotherapy of Cancer. He served as a Member of the steering committee for the CRI-CIC from 2006 to 2011. He is Group Chair of the SITC Biomarker Task Force and the Chair of the SITC Tumor Mutational Burden subcommittee.

Ke Liu, MD, PhD (Co-Chair)

Ke Liu, MD, PhD, is Chief Development Officer of Marengo Therapeutics. Ke has over 20 years of experience in the field of oncology, immuno-oncology, and cell and gene therapy, most recently serving as Senior Vice President and led the key regulatory activities at Sana Biotechnology. Prior to Sana, he spent more than 17 years working at the U.S. Food and Drug Administration (FDA) where he held leadership roles at the Center for Biologics Evaluation and Research (CBER), Center for Drug Evaluation and Research (CDER), and the Oncology Center of Excellence (OCE). Ke has made major contributions to the field of Oncology and led the clinical evaluations and approvals of key first-in-class cancer therapeutics over the past decade, including checkpoint inhibitors, chimeric antigen receptor (CAR) T cells, T cell receptor (TCR) modified T cells, genome-edited products, neoantigen-based therapies, adoptive T cell therapies, oncolytic viral therapy, dendritic cell therapy, and combinations of these immune-oncologic therapeutics with checkpoint inhibitors and other agents.

Ke received his M.D. from Henan Medical University in China and his Ph.D. in molecular biology from Cornell University. He completed his internal medicine internship and residency at Albert Einstein College of Medicine, his medical oncology fellowship at the National Cancer Institute (NCI), and additional cancer immunotherapy training at the NCI’s Surgery Branch. Ke is an internist and medical oncologist certified by the American Board of Internal Medicine.

Yufeng Li, PhD

Yufeng Li, PhD, is currently Director of Clinical Science at Vivace Therapeutics, based in Philadelphia, PA.

Yufeng graduated from Shanghai Jiao Tong University, and obtained PhD training at UT MD Anderson Cancer Center at Houston, focusing on cancer immunology and immunotherapy. Subsequently, he spent many years at GSK to discover and develop medicines for cancer patients. Prior to Vivace, Yufeng has also served biotech companies (Ascentage, Transcenta, and Qilu) to oversee their US and global clinical programs.

Yufeng is active for community-based volunteer activities, including serving important roles in organizations such as Sino-American Pharmaceutical Professionals Association (SAPA), the Main Line Chinese Culture Center (MLCCC) etc.

Zhaohui Jin, MD

Dr. Zhaohui Jin received his MD at the Peking Union Medical College in Beijing, China then worked in the Department of hematology at the Sixth People’s Hospital of Shanghai. Dr. Jin came to the United States working as a research fellow at the Shands cancer center, University of Florida in 2002. Dr. Jin moved to Boston and worked as an instructor at the Harvard medical school between 2005-2010. Subsequently Dr. Jin completed residency training in New Jersey followed by hematology/oncology fellowship in Iowa. Dr. Jin completed his advanced GI oncology fellowship at the Mayo Clinic in 2017. He worked as a clinical assistant professor at the University of Illinois Urbana-Champaign (UIUC) for a year before his returned to the Mayo Clinic in February 2019. Dr. Jin is now a GI medical oncologist and the practice chair for GI tumor group at the Department of Medical Oncology.

Oliver Kong, MD

Dr. Oliver Kong currently served as Chief Medical Officer of Chengdu New Radio-medicine Technology Company and its business covers research, manufacture and sales for medical isotopes and products and services for malignant tumor diagnosis and treatments and radionuclides medicine technology support and consulting. Before joined NRT Radio-medicine, Dr. Kong was Chief Medical Officer of IASO BIO, a CAR-T Biotech company. Before that, Dr. Kong served as Chief Medical Officer and Group Vice President of Qilu Pharmaceutical Company, oversaw the clinical research and development of Qilu's clinical innovative drugs and biosimilar drugs. Before he joined Qilu, he was Vice President of Clinical Oncology of Hengrui USA. He previously served as the Global Medical Unit Head for Breast Cancer at Novartis Oncology. He also served as Senior Medical Director of Celgene Corporation and US Medical Director of Bayer Pharmaceuticals. He has over 25 years of experience in the pharmaceutical industry in clinical development and medical fields in various disease or therapeutic areas prior to oncology, autoimmune and infectious diseases.

Chung-Han Lee, MD, PhD

COMING SOON

Jerry Huang, MD, PhD, MBA